Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln

Moderna's 2025 revenue outlook slightly beats expectations, indicating a modestly optimistic growth trajectory.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Conference Calendar - 12th January 2026: BMY, JNJ, BA, MCK, MSI, NKE, NOC

Boston Scientific (BSX) announces an agreement to acquire Valencia Technologies Corporation; exp. to complete in H1'26 and have an immaterial impact to Adj. EPS

Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln

EU Commission Spokesperson says that they stand ready to propose new and more severe sanctions on Iran

BioNTech (BNTX) says 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Cash, cash equivalents and investments at year-end 2025 about USD 8.1bln.
  • Expects GAAP operating expenses of USD 4.2-4.6bln in 2027, targeting cash breakeven in 2028.
  • Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026.
  • Potential first approvals of flu and flu/covid combination products in 2026.
Context

The decrease in expected operating expenses suggests improved cost management, which, paired with their growth forecast and potential product approvals, could enhance investor sentiment. This performance insight is crucial for evaluating Moderna's positioning in the biotech sector and its impact on stock valuation.

Related headlines

The whole workspace, free to try.

Try it free